Fenbendazole is a widely used benzimidazole anthelmintic drug with broad antiparasitic activity against various gastrointestinal parasites, such as pinworms, giardia, roundworms, hookworms, whipworms, and tapeworms (common brands are Pancur and Safe-Guard). It has also been reported to have antitumor effects in several animal models by inhibiting microtubule polymerization via tubulin binding.
Recently, it has been found that fenbendazole may prevent tumor growth and metastasis by inducing apoptosis. However, fenbendazole has not been approved by Health Canada for cancer treatment. While it is currently classified as a veterinary medication, research into its potential to treat cancer has begun.
In this study, we conducted interviews with cancer patients who self-administer fenbendazole in order to learn about how they acquire the information and their perceptions about it. In total, we interviewed 21 participants, ages 56 to 75 years, who were diagnosed with lung cancer three months to five years ago. They were in stage one to four of the disease.
The participants were divided into two groups based on how they acquired their information about fenbendazole. Group one included those who had heard about the medication from a friend or family member. Group two included those who had learned about it from the Internet or a book. They were interviewed about their acquisition process, how they analyzed the information, and their perceived quality. They were also asked to provide the sources of their information about fenbendazole and cancer. Finally, they were asked whether they believed the information about fenbendazole to be true or false. fenbendazole for cancer